Dysregulation of PRCs can lead to aberrant gene silencing, contributing to oncogenesis. For instance, overexpression of EZH2, a core component of PRC2, is found in several cancers, including prostate, breast, and lymphomas. This overexpression can lead to the excessive repression of tumor suppressor genes, thereby promoting uncontrolled cell proliferation.
